KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $47.9 million.

  • Adaptive Biotechnologies' Cash & Equivalents rose 44.51% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 44.51%. This contributed to the annual value of $47.9 million for FY2024, which is 26.35% down from last year.
  • As of FY2024, Adaptive Biotechnologies' Cash & Equivalents stood at $47.9 million, which was down 26.35% from $65.1 million recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' Cash & Equivalents ranged from a high of $139.1 million in FY2021 and a low of $47.9 million during FY2024.
  • For the 3-year period, Adaptive Biotechnologies' Cash & Equivalents averaged around $67.7 million, with its median value being $65.1 million (2023).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Cash & Equivalents grew by 27.81% in 2020, and later plummeted by 35.26% in 2022.
  • Adaptive Biotechnologies' Cash & Equivalents (Yearly) stood at $123.4 million in 2020, then increased by 12.66% to $139.1 million in 2021, then slumped by 35.26% to $90.0 million in 2022, then fell by 27.73% to $65.1 million in 2023, then decreased by 26.35% to $47.9 million in 2024.